Related Experiment Video
Updated: Aug 8, 2026

09:29
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
Published on: February 12, 2015
Strontium-89 therapy for painful osseous metastatic prostate and breast cancer
D V Hansen1, E R Holmes, G Catton
1Sacred Heart Medical Center, Spokane, Washington.
American Family Physician
|June 1, 1993
Abstract:
Strontium-89 chloride is a radiopharmaceutical that localizes to actively forming new bone, such as metastatic bone lesions from prostate and breast cancer. It provides effective systemic endo-osseous local radiation therapy to these painful lesions. Strontium-89 will soon be available to physicians in the United States for use in the palliative management of metastatic bone pain.

